Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

被引:9
作者
Guo, Yang [1 ]
Cao, Xue-Shan [2 ]
Yang, Hua-Tong [3 ,4 ]
Zhou, Meng-Ge [5 ]
Yu, Bo [1 ,6 ]
机构
[1] Hong Kong Univ Sci & Technol, Shenzhen Peking Univ, Peking Univ Shenzhen Hosp, Inst Dermatol,Dept Dermatol,Med Ctr, Shenzhen, Peoples R China
[2] Shenzhen Univ, Coll Life Sci & Oceanog, Shenzhen, Peoples R China
[3] Southern Univ Sci & Technol, Dept Stat & Data Sci, Shenzhen, Peoples R China
[4] Univ Calif Berkeley, Dept Stat, Berkeley, CA USA
[5] Chinese Acad Med Sci, Peking Union Med Coll, Sch Basic Med, Dept Epidemiol & Biostat,Inst Basic Med Sci, Beijing, Peoples R China
[6] Hong Kong Univ Sci & Technol, Shenzhen Peking Univ, Med Ctr, Dept Dermatol,Inst Dermatol,Shenzhen Hosp, China 1120,Lianhua Rd, Shenzhen 518036, Guangdong, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
SAFETY; WORKERS;
D O I
10.7189/jogh.13.06008
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Understanding the incidence pattern of cutaneous reactions is crucial for promoting COVID-19 vaccination. We aimed to report the global incidence pattern of, and factors associated with common cutaneous reac-tions related to COVID-19 vaccination in real-world settings.Methods We searched five databases (PubMed, Web of Science, Embase, CNKI, and Wanfang) from inception to May 13, 2022, for studies reporting the incidence of common cutaneous reactions related to COVID-19 vaccines in real-world settings. The outcomes were the systematic skin reactions (rash and urticaria) and the local injection site reactions (pain, swelling, redness, and erythema). We conducted random-effects meta-analyses and explored associated factors using multi-step statistical analyses.Results We included 35 studies and assessed 2 549 968 participants from 23 countries. The pooled incidence of overall systemic skin reactions was 3.8% (95% confidence interval (CI) = 2.4%-5.5%) with short duration (about one week). Specifically, the pooled incidence rates of rash and urticaria were 3.0% (95% CI = 2.1%-3.9%) and 1.1% (95% CI = 0.7%-1.5%), respectively. For overall local injection site reactions, the pooled incidence was 72.4% (95% CI = 65.7%-78.7%) with short duration (1 to 4.5 days). Except for local pain (72.2%, 95% CI = 65.3%-78.5%), other localized reactions had low incidence, including swelling (13.3%, 95% CI = 9.5%-17.7%), redness (11.5%, 95% CI = 5.7%-19.0%), and erythema (5.8%, 95% CI = 0.7%-15.4%). Geographical-ly, different distribution patterns were observed for these reactions. Regard-ing associated factors, mRNA vaccines showed lower incidence of urticaria (P < 0.001). Asia population showed higher incidence of urticaria (P < 0.001). We observed lower incidence rates of overall local injection site reactions and pain among inactivated vaccines (P < 0.001). We found no significant dif-ference among reactions between the first and the second dose of vaccines.Conclusions We examined the global incidence pattern of common cutane-ous reactions related to COVID-19 vaccination and found low incidence and short duration of systemic skin reactions and local injection site reactions (ex-cept for pain); discrepancies in these reactions were observed across different vaccine types. The cutaneous side effects related to COVID-19 vaccination do not seem to cause concern.
引用
收藏
页数:17
相关论文
共 64 条
  • [1] Abbafati C, 2020, LANCET, V396, P1204
  • [2] Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine
    Ackerman, M.
    Henry, D.
    Finon, A.
    Binois, R.
    Esteve, E.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (07) : E423 - E425
  • [3] Safety of COVID-19 vaccines
    Aga, Qutaiba A. Al Khames
    Alkhaffaf, Waseem H.
    Hatem, Tagreed H.
    Nassir, Kawthar F.
    Batineh, Yazan
    Dahham, Abdullah T.
    Shaban, Dimah
    Aga, Luma A. Al Khames
    Agha, Manhal Y. R.
    Traqchi, Muaamar
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (12) : 6588 - 6594
  • [4] Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
    Al Bahrani, Salma
    Albarrak, Ali
    Alghamdi, Othman Ali
    Alghamdi, Mesfer Abdullah
    Hakami, Fatimah H.
    Al Abaadi, Asmaa K.
    Alkhrashi, Sausan A.
    Alghamdi, Mansour Y.
    Almershad, Meshael M.
    Alenazi, Mansour Moklif
    El Gezery, Mohamed Hany
    Jebakumar, Arulanantham Zechariah
    Al-Tawfiq, Jaffar A.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 110 : 359 - 362
  • [5] Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis
    Aldridge, Robert W.
    Story, Alistair
    Hwang, Stephen W.
    Nordentoft, Merete
    Luchenski, Serena A.
    Hartwell, Greg
    Tweed, Emily J.
    Lewer, Dan
    Katikireddi, Srinivasa Vittal
    Hayward, Andrew C.
    [J]. LANCET, 2018, 391 (10117) : 241 - 250
  • [6] Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis
    Alhumaid, Saad
    Al Mutair, Abbas
    Al Alawi, Zainab
    Rabaan, Ali A.
    Tirupathi, Raghavendra
    Alomari, Mohammed A.
    Alshakhes, Aqeel S.
    Alshawi, Abeer M.
    Ahmed, Gasmelseed Y.
    Almusabeh, Hassan M.
    Alghareeb, Tariq T.
    Alghuwainem, Abdulaziz A.
    Alsulaiman, Zainab A.
    Alabdulmuhsin, Mohammed A.
    AlBuwaidi, Emad A.
    Dukhi, Amjad K. Bu
    Mufti, Hani N.
    Al-Qahtani, Manaf
    Dhama, Kuldeep
    Al-Tawfiq, Jaffar A.
    Al-Omari, Awad
    [J]. ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2021, 17 (01)
  • [7] Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Ali, Haris
    Ngo, Dat
    Aribi, Ahmed
    Arslan, Shukaib
    Dadwal, Sanjeet
    Marcucci, Guido
    Nakamura, Ryotaro
    Forman, Stephen J.
    Chen, Jason
    Al Malki, Monzr M.
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (11): : 938.e1 - 938.e6
  • [8] Araminda Gn, 2022, Int. J. Appl. Pharm., P37
  • [9] Atteno M, 2021, ANN RHEUM DIS, V15, P13
  • [10] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416